Abstract Search

ea0081oc3.2 | Oral Communications 3: Thyroid 1 | ECE2022

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-Targeted yherapy: updated results from the phase 3 COSMIC-311 trial and prespecified subgroup analyses based on prior therapy

Durante Cosimo , Brose Marcia , Robinson Bruce , Sherman Steven I , Jarzab Barbara , Lin Chia-Chi , Vaisman Fernanda , Hoff Ana O , Hitre Erika , Bowles Daniel W , Sen Suvajit , Patel Purvi , Keam Bhumsuk , Capdevila Jaume

Background: At a preplanned interim analysis (median follow-up 6.2 months) of the double-blind, phase 3 COSMIC-311 trial (NCT03690388), cabozantinib significantly improved progression-free survival (PFS) vs placebo (HR 0.22, 96% CI 0.13-0.36; P<0.0001) in 187 patients with previously treated radioiodine-refractory DTC (Brose, Lancet Oncol; 2021). Patients must have received lenvatinib or sorafenib and progressed during or after 1-2 prior VEGFR inhibitors. We prese...

0 shares

ea0081oc3.4 | Oral Communications 3: Thyroid 1 | ECE2022

Effect of age on efficacy and safety of cabozantinib vs placebo in patients with radioiodine refractory (RAI-R)-differentiated thyroid cancer (DTC) with progression after VEGFR-targeted therapy: subgroup analysis from Phase 3 COSMIC 311 study

Durante Cosimo , Robinson Bruce , Sherman Steven I , Krajewska Jolanta , Lin Chia-Chi , Vaisman Fernanda , Hoff Ana O , Hitre Erika , Bowles Daniel W , Hernando Jorge , Banerjee Kamalika , Levytskyy Roman M , Oliver Jennifer W , Keam Bhumsuk , Capdevila Jaume , Brose Marcia

Background: Increasing age is associated with poorer survival in DTC [Oyer SL, 2012]. In the phase 3 COSMIC-311 trial (NCT03690388), cabozantinib, an inhibitor of VEGFR2, MET, AXL and RET, significantly improved the progression-free survival (PFS) vs placebo in previously treated patients with RAI-R DTC (HR 0.22, 96% CI 0.13-0.36; P<0.0001; median follow-up 6.2 months). The impact of age on efficacy and safety was included in the prespecified subgroup analysis.</p...

0 shares

Endocrine Abstracts

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-Targeted yherapy: updated results from the phase 3 COSMIC-311 trial and prespecified subgroup analyses based on prior therapy

Effect of age on efficacy and safety of cabozantinib vs placebo in patients with radioiodine refractory (RAI-R)-differentiated thyroid cancer (DTC) with progression after VEGFR-targeted therapy: subgroup analysis from Phase 3 COSMIC 311 study

BiosciAbstracts